Why the study?
Mechanisms for worse prognosis after myocardial infarction in low socioeconomic status are unclear, motivating an investigation into its association with discontinuation of evidence-based secondary prevention drug therapies.
Does low socioeconomic status increase the risk of discontinuation of evidence-based secondary prevention therapies in patients after a first-ever myocardial infarction?
Does low socioeconomic status increase the risk of discontinuation of evidence-based secondary prevention therapies in patients after a first-ever myocardial infarction?
Lower income and immigrant background are significantly associated with higher rates of discontinuation of evidence-based secondary prevention therapies after myocardial infarction, even in a universal healthcare system.
Socioeconomic disparities may drive higher post-MI discontinuation; this Level 3 evidence leaves open effective mitigation strategies.
BACKGROUND: Mechanisms for worse prognosis after myocardial infarction in low socioeconomic status are unclear. We therefore investigated the association between socioeconomic status and discontinuation of evidence-based secondary prevention drug therapies. METHODS: All patients with a first-ever myocardial infarction, on treatment with a statin (n=60 717), antithrombotic therapy (n=65 862), or a renin-angiotensin-aldosterone-system inhibitor (n=51 486) at the routine 1-year visit in SWEDEHEART (Swedish Web-System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies) between January 2006 and mid-2020 were included in this population-based nationwide cohort study. Individual-level socioeconomic status was measured by disposable income quintile, region of birth, and educational level. Outcomes were discontinuation (>180 days without a new prescription claim) of statins, antithrombotic therapies, and renin-angiotensin-aldosterone-system-inhibitors. Bias-minimized multivariable adjusted hazard ratios (aHRs) were estimated during follow-up until December 2020. RESULTS: Discontinuation occurred more often in the lowest versus highest income quintile for statins (aHR, 1.25 [95% CI, 1.20-1.31]), antithrombotic therapy (aHR, 1.26 [95% CI, 1.20-1.32]), and renin-angiotensin-aldosterone-system inhibitors (aHR, 1.32 [95% CI, 1.26-1.39]). Discontinuation of statins was more frequent among immigrants (versus nonimmigrants) born in other Nordic (aHR, 1.24 [95% CI, 1.17-1.32]), other European (aHR, 1.40 [95% CI, 1.33-1.47]), Asian (aHR, 1.45 [95% CI, 1.36-1.56]), and other world regions (aHR, 1.63 [95% CI, 1.45-1.84]). Associations between immigrant background and discontinuation of antithrombotic therapies and renin-angiotensin-aldosterone-system inhibitors were even stronger. Lower (versus tertiary) educational level was inversely associated with discontinuation of secondary prevention drug classes. CONCLUSIONS: Despite Swedish universal health care, discontinuation of evidence-based drugs post myocardial infarction is strongly associated with disposable income and immigrant background. Further study on strategies to improve adherence in low socioeconomic status post myocardial infarction is warranted.
No takes yet. Share an insight, caveat, or question.
Ohm et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: